Results 121 to 130 of about 13,000,271 (286)
Use of a BamHI polymorphism in the factor IX gene for the determination of hemophilia B carrier status [PDF]
, 1986 CW Hay +5 more
openalex +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Haemophilia is a bleeding disorder caused by a deficiency in coagulation factors VIII or IX. Great advances in haemophilia treatment have been achieved in recent decades, with a range of products for prophylaxis now available, the ability to individualise therapy, and resultant improvements in life expectancy and quality of life ...
Allison P. Wheeler +6 more
wiley +1 more source
The Application of Clinical Genetics, 2023 Ampaiwan Chuansumrit,1 Rungrote Natesirinilkul,2 Nongnuch Sirachainan,1 Praguywan Kadegasem,1 Pacharapan Surapolchai,3 Noppawan Tangbubpha,1 Ketsuda Kempka,1 Tanyanee Khlangtan1 1Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital ...
Chuansumrit A +7 more
doaj
Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene [PDF]
, 1985 H. J. Hassan +8 more
openalex +1 more source
Factors Influencing Symptoms of Depression, Anxiety and Stress in Patients With Haemophilia
Haemophilia, EarlyView.ABSTRACT Introduction Patients with haemophilia (PwH) often suffer from psychological symptoms such as depression or anxiety. To date, uncertainty exists about the determinants predicting worse psychological outcomes. Therefore, this study aimed to investigate the extent of depressive, anxiety and stress‐related symptoms in PwH compared to the healthy ...
Alexander Schmidt +7 more
wiley +1 more source
A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B [PDF]
, 1986 Michel Vidaud +5 more
openalex +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Currently, physical health assessments in persons with haemophilia focus on bleed‐related events and after‐effects. The aim of the systematic review was to review and apply standardised criteria to evaluate reliability, responsiveness and construct validity of performance‐based instruments evaluating physical capability in persons
Catherine Holdsworth +9 more
wiley +1 more source
Treatment of hemophilia B: focus on recombinant factor IX
Biologics: Targets & Therapy, 2013 Massimo Franchini, Francesco Frattini, Silvia Crestani, Cinzia Sissa, Carlo BonfantiDepartment of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, ItalyAbstract: Hemophilia B is a recessive X-linked bleeding disorder characterized by ...
Franchini M +4 more
doaj
MOLECULAR BASIS OF HEMOPHILIA B: IDENTIFICATION OF THE DEFECT IN FACTOR IX VANCOUVER [PDF]
, 1987 V A Geddes +3 more
openalex +1 more source
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors
Haemophilia, EarlyView.Introduction Eptacog beta is an activated recombinant human factor VII bypassing agent approved for treating bleeding episodes (BEs) in patients aged ≥12 years with haemophilia A or B with inhibitors. Two initial dose regimens (IDRs) of either 75 or 225 µg/kg, followed by 75 µg/kg, are approved.
Manuel Carcao +7 more
wiley +1 more source